We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-8.93%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.34B
AUM Growth
-$295M
Cap. Flow
-$42.8M
Cap. Flow %
-3.19%
Top 10 Hldgs %
61.63%
Holding
43
New
8
Increased
12
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
AKBA icon
Akebia Therapeutics
AKBA
+$55.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$53.4M
3
CYTK icon
Cytokinetics
CYTK
+$43.8M
4
UTHR icon
United Therapeutics
UTHR
+$41M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$40.2M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$134M
2
ALGN icon
Align Technology
ALGN
+$75.1M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$63.2M
4
EXAS
Exact Sciences
EXAS
+$53.6M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$41.8M

Sector Composition

Rank Sector Weight
1 Healthcare 90.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$10.8M 0.81%
3,150,565
-275,800
-8% -$1.61M
ADMA icon
27
ADMA Biologics
ADMA
$2.22B
$9.74M 0.73%
3,383,290
-1,783,671
-35% -$6.17M
SIOX
28
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$8.91M 0.66%
+3,653,303
New +$13.2M
OVID icon
29
Ovid Therapeutics
OVID
$491M
$7.69M 0.57%
2,580,878
-308,010
-11% -$1.04M
BEAT
30
DELISTED
BioTelemetry, Inc.
BEAT
$1.9M 0.14%
49,219
-105,781
-68% -$4.87M
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$268K 0.02%
10,000
-125,000
-93% -$4.44M
ALGN icon
32
Align Technology
ALGN
$12.3B
– –
-269,000
Closed -$75.1M
EXAS
33
DELISTED
Exact Sciences
EXAS
– –
-579,666
Closed -$53.6M
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
– –
-507,739
Closed -$4.95M
IOVA icon
35
Iovance Biotherapeutics
IOVA
$2.87B
– –
-1,509,327
Closed -$41.8M
PODD icon
36
Insulet
PODD
$9.79B
– –
-155,800
Closed -$26.7M
STAA icon
37
STAAR Surgical
STAA
$1.21B
– –
-425,800
Closed -$15M
TNDM icon
38
Tandem Diabetes Care
TNDM
$1.56B
– –
-550,956
Closed -$32.8M
VCEL icon
39
Vericel Corp
VCEL
$2.31B
– –
-1,556,137
Closed -$27.1M
MOR
40
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-21,561
Closed -$769K
TPTX
41
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-71,300
Closed -$4.44M
GWPH
42
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-604,604
Closed -$63.2M
ARQL
43
DELISTED
Arqule Inc
ARQL
– –
-6,715,965
Closed -$134M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Consonance Capital Management held 43 positions worth $1.34B, down 18% from $1.64B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Consonance Capital Management withdrew a net $42.8M in Q1 2020, closing 12 positions and reducing 9 holdings. Its most notable exit was Arqule Inc, an estimated $134M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Akebia Therapeutics worth $54M.

  • Consonance Capital Management's largest Q1 2020 buy was Akebia Therapeutics: 7,121,283 shares worth $54M.
  • Consonance Capital Management added most to Sarepta Therapeutics in Q1 2020, an estimated $53.4M increase.
  • Consonance Capital Management's biggest Q1 2020 reduction was Epizyme, Inc, cutting an estimated $21.5M.
  • Consonance Capital Management fully exited Arqule Inc in Q1 2020, selling an estimated $134M.
  • Consonance Capital Management's ten largest holdings make up 62% of its $1.34B portfolio in Q1 2020.
  • Consonance Capital Management opened 8 new positions and closed 12 in Q1 2020.
  • Consonance Capital Management's portfolio value fell 18% quarter-over-quarter to $1.34B.

Based on Consonance Capital Management's 13F filing for Q1 2020, filed 15 May 2020.